vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and loanDepot, Inc. (LDI). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $185.2M, roughly 1.7× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -7.2%, a 8.2% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 20.5%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $-648.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 18.0%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
FOLD vs LDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $310.3M |
| Net Profit | $1.7M | $-22.5M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | -10.3% |
| Net Margin | 0.9% | -7.2% |
| Revenue YoY | 23.7% | 20.5% |
| Net Profit YoY | -88.5% | 32.4% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $310.3M | ||
| Q3 25 | $169.1M | $323.3M | ||
| Q2 25 | $154.7M | $282.5M | ||
| Q1 25 | $125.2M | $273.6M | ||
| Q4 24 | $149.7M | $257.5M | ||
| Q3 24 | $141.5M | $314.6M | ||
| Q2 24 | $126.7M | $265.4M | ||
| Q1 24 | $110.4M | $222.8M |
| Q4 25 | $1.7M | $-22.5M | ||
| Q3 25 | $17.3M | $-4.9M | ||
| Q2 25 | $-24.4M | $-13.4M | ||
| Q1 25 | $-21.7M | $-21.9M | ||
| Q4 24 | $14.7M | $-33.2M | ||
| Q3 24 | $-6.7M | $1.4M | ||
| Q2 24 | $-15.7M | $-32.2M | ||
| Q1 24 | $-48.4M | $-34.3M |
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | 8.6% | -10.3% | ||
| Q3 25 | 20.3% | -3.2% | ||
| Q2 25 | -6.1% | -11.4% | ||
| Q1 25 | -6.3% | -16.8% | ||
| Q4 24 | 10.7% | -32.7% | ||
| Q3 24 | 15.3% | 1.1% | ||
| Q2 24 | 11.8% | -29.1% | ||
| Q1 24 | -25.1% | -38.2% |
| Q4 25 | 0.9% | -7.2% | ||
| Q3 25 | 10.2% | -1.5% | ||
| Q2 25 | -15.8% | -4.7% | ||
| Q1 25 | -17.3% | -8.0% | ||
| Q4 24 | 9.8% | -12.9% | ||
| Q3 24 | -4.8% | 0.4% | ||
| Q2 24 | -12.4% | -12.1% | ||
| Q1 24 | -43.9% | -15.4% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.02 | $0.01 | ||
| Q2 24 | $-0.05 | $-0.18 | ||
| Q1 24 | $-0.16 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $337.2M |
| Total DebtLower is stronger | $392.7M | $2.1B |
| Stockholders' EquityBook value | $274.2M | $386.0M |
| Total Assets | $949.9M | $6.9B |
| Debt / EquityLower = less leverage | 1.43× | 5.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $337.2M | ||
| Q3 25 | $263.8M | $459.2M | ||
| Q2 25 | $231.0M | $408.6M | ||
| Q1 25 | $250.6M | $371.5M | ||
| Q4 24 | $249.9M | $421.6M | ||
| Q3 24 | $249.8M | $483.0M | ||
| Q2 24 | $260.1M | $533.2M | ||
| Q1 24 | $239.6M | $603.7M |
| Q4 25 | $392.7M | $2.1B | ||
| Q3 25 | $392.0M | $2.1B | ||
| Q2 25 | $391.3M | $2.1B | ||
| Q1 25 | $390.7M | $2.0B | ||
| Q4 24 | $390.1M | $2.0B | ||
| Q3 24 | $389.5M | $2.0B | ||
| Q2 24 | $388.9M | $2.0B | ||
| Q1 24 | $388.4M | $2.3B |
| Q4 25 | $274.2M | $386.0M | ||
| Q3 25 | $230.4M | $433.3M | ||
| Q2 25 | $204.3M | $439.1M | ||
| Q1 25 | $193.6M | $469.3M | ||
| Q4 24 | $194.0M | $506.6M | ||
| Q3 24 | $178.8M | $592.0M | ||
| Q2 24 | $132.5M | $578.9M | ||
| Q1 24 | $130.7M | $637.3M |
| Q4 25 | $949.9M | $6.9B | ||
| Q3 25 | $868.8M | $6.2B | ||
| Q2 25 | $815.3M | $6.2B | ||
| Q1 25 | $789.8M | $6.4B | ||
| Q4 24 | $785.0M | $6.3B | ||
| Q3 24 | $786.6M | $6.4B | ||
| Q2 24 | $749.5M | $5.9B | ||
| Q1 24 | $721.8M | $6.2B |
| Q4 25 | 1.43× | 5.44× | ||
| Q3 25 | 1.70× | 4.83× | ||
| Q2 25 | 1.92× | 4.70× | ||
| Q1 25 | 2.02× | 4.30× | ||
| Q4 24 | 2.01× | 4.00× | ||
| Q3 24 | 2.18× | 3.31× | ||
| Q2 24 | 2.93× | 3.41× | ||
| Q1 24 | 2.97× | 3.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $-638.7M |
| Free Cash FlowOCF − Capex | $16.0M | $-648.0M |
| FCF MarginFCF / Revenue | 8.6% | -208.9% |
| Capex IntensityCapex / Revenue | 0.2% | 3.0% |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $-734.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $-638.7M | ||
| Q3 25 | $35.7M | $43.4M | ||
| Q2 25 | $-26.5M | $67.6M | ||
| Q1 25 | $7.8M | $-179.9M | ||
| Q4 24 | $-3.9M | $47.7M | ||
| Q3 24 | $-23.0M | $-349.2M | ||
| Q2 24 | $22.7M | $-278.3M | ||
| Q1 24 | $-29.7M | $-278.5M |
| Q4 25 | $16.0M | $-648.0M | ||
| Q3 25 | $35.3M | $38.7M | ||
| Q2 25 | $-28.9M | $61.4M | ||
| Q1 25 | $7.5M | $-186.7M | ||
| Q4 24 | $-4.2M | $40.8M | ||
| Q3 24 | $-23.3M | $-356.4M | ||
| Q2 24 | $21.6M | $-285.7M | ||
| Q1 24 | $-31.5M | $-283.3M |
| Q4 25 | 8.6% | -208.9% | ||
| Q3 25 | 20.9% | 12.0% | ||
| Q2 25 | -18.7% | 21.7% | ||
| Q1 25 | 6.0% | -68.2% | ||
| Q4 24 | -2.8% | 15.8% | ||
| Q3 24 | -16.5% | -113.3% | ||
| Q2 24 | 17.0% | -107.7% | ||
| Q1 24 | -28.5% | -127.2% |
| Q4 25 | 0.2% | 3.0% | ||
| Q3 25 | 0.2% | 1.5% | ||
| Q2 25 | 1.6% | 2.2% | ||
| Q1 25 | 0.2% | 2.5% | ||
| Q4 24 | 0.2% | 2.7% | ||
| Q3 24 | 0.3% | 2.3% | ||
| Q2 24 | 0.9% | 2.8% | ||
| Q1 24 | 1.6% | 2.1% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | -255.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
LDI
Segment breakdown not available.
